Introduction {#j_jomb-2018-0007_s_001}
============

Vitamin D (Vit D) is involved in a broad variety of biological processes ([@j_jomb-2018-0007_ref_001]) and plays a major role in many hormonal and metabolic disorders associated with the female reproductive system, such as Polycystic Ovary Syndrome (PCOS) ([@j_jomb-2018-0007_ref_002]). Most of the processes brought about by Vit D are mediated through its binding to the Vit D receptor (VDR) ([@j_jomb-2018-0007_ref_003]). The *VDR* is a member of the nuclear receptor superfamily and is spread across different tissues, including intestine, kidney, parathyroid gland, pancreatic beta calls, and bones, all involved in maintenance of calcium homeostasis. It is also expressed in human ovarian tissue and in the human endometrium ([@j_jomb-2018-0007_ref_004], [@j_jomb-2018-0007_ref_005]), and is shown to have a role in steroidogenesis of sex hormones ([@j_jomb-2018-0007_ref_006]). Recently, considerable interest has focused on the pathogenesis of PCOS, since it is one of the most common endocrine disorders in women of childbearing age and has a strong genetic predisposition ([@j_jomb-2018-0007_ref_007]). Some studies have implicated an involvement of mutant *VDR* gene in the pathogenesis of PCOS. Other studies have shown an association between PCOS and Vit D deficiency and insulin resistance ([@j_jomb-2018-0007_ref_008], [@j_jomb-2018-0007_ref_009], [@j_jomb-2018-0007_ref_010], [@j_jomb-2018-0007_ref_011]). A higher prevalence of Vit D deficiency has been reported in women with PCOS ([@j_jomb-2018-0007_ref_012], [@j_jomb-2018-0007_ref_013]) and since the physiological effect of Vit D is dependent on the VDR, several investigations have been directed to study the genetic mutations and polymorphisms in *VDR* in PCOS patients ([@j_jomb-2018-0007_ref_014], [@j_jomb-2018-0007_ref_015], [@j_jomb-2018-0007_ref_016], [@j_jomb-2018-0007_ref_017]).

The *VDR* Gene is located on chromosome 12q13.11 and spans about 75kb with 11 exons. Many allelic variants due to single nucleotide polymorphisms (SNP) have been reported in the *VDR* gene and differences are obvious in different racial groups ([@j_jomb-2018-0007_ref_001], [@j_jomb-2018-0007_ref_018],[@j_jomb-2018-0007_ref_019][@j_jomb-2018-0007_ref_020]). Wehr and coworkers ([@j_jomb-2018-0007_ref_021]) reported no significant influence of genetic variations and PCOS susceptibility, but *VDR* and Vit D level-related variants were shown to be associated with some disorders in PCOS including Vit D levels. Mahmoudi and coworkers ([@j_jomb-2018-0007_ref_022]) reported that the ApaI (rs7975232) genotype »AA« could be considered as a marker of decreased susceptibility for PCOS, while the »aa« genotype was associated with an increased risk for PCOS. Mcgrath et al. ([@j_jomb-2018-0007_ref_023]) showed that there was a significant relationship between rs10735810 (merged with rs2228570) and levels of Vit D, and the T allele was associated with higher concentrations of Vit D. In contrast, Bagheri et al. ([@j_jomb-2018-0007_ref_024]) reported no statistically significant association with PCOS susceptibility. Wehr et al. ([@j_jomb-2018-0007_ref_021]), found that ApaI (rs7975232) variants are associated with testosterone levels in PCOS patients. A study from Iran reported an association between *VDR* TaqI (rs731236) (CC) genotype, and serum levels of LH ([@j_jomb-2018-0007_ref_025]). This finding was confirmed by Bagheri and coworkers ([@j_jomb-2018-0007_ref_026]).

Since there are several contradictory reports of association between SNPs in *VDR* and PCOS and associated hormonal abnormalities, we designed this study to investigate the levels of Vit D and polymorphism in *VDR* gene in Saudi females with and without PCOS and to correlate the findings to demographic and hormonal values in the two groups.

Materials and Methods {#j_jomb-2018-0007_s_002}
=====================

Study population {#j_jomb-2018-0007_s_002_s_001}
----------------

The study was approved by the Institutional Ethical Committee, and an IRB was obtained. Each female who volunteered to join in the study, was explained the nature of the study and a signed informed consent was obtained. The study group included 33 women with age ranging from 18-36 years (16 women suffering from PCOS and 17 healthy women as normal controls). The PCOS patients were attending clinics at the An Noor Hospital in Makkah Al Mukarama and were diagnosed

using the Rotterdam criteria ([@j_jomb-2018-0007_ref_027]). A women was diagnosed as PCOS if she had at least 2 of the following criteria \[menstrual abnormalities either amenorrhea (absence of periods for more than 6 months) or oligomenorrhea (fewer than six menstrual periods in the preceding year) and the appearance of oversized ovaries with the presence of more than 12 ovarian follicles by ultrasound scanning ([@j_jomb-2018-0007_ref_021]). In addition, all 16 women with PCOS were Saudis and were genetically unrelated. The controls were normal healthy females with regular menstrual cycle and no indications of sign and symptoms of PCOS or any other gynecological problem. History was taken and standard anthropometric data \[height (cm), weight (Kg) and body mass index (BMI) (kg/m^2^)\] were obtained from each patient and control.

Sample collection {#j_jomb-2018-0007_s_002_s_002}
-----------------

Fasting blood samples (10 mL) were collected by venipuncture in tubes with no anti-coagulant, for analyses of the hormones, and in EDTA tubes for DNA extraction. The samples were immediately centrifuged to obtain the serum which was stored at −20 °C until required for analysis.

Biochemical analysis {#j_jomb-2018-0007_s_002_s_003}
--------------------

The serum was used for the analysis of luteinizing hormone (LH), follicle stimulating hormone (FSH) and Vit D. The measurements of LH and FSH were made using Enzyme Linked Immuno Sorbent Assay (ELISA) from (Phoenix Pharmaceuticals, Inc., Belmont, CA, USA) and the Vit D level was assayed by ELISA, using kits from EagleBio (Inc, Nashua).

DNA extraction {#j_jomb-2018-0007_s_002_s_004}
--------------

Genomic DNA was extracted from blood using DNA Extraction kits (QIAGEN) (Catalog Number: 158359), for each PCOS patient and the control sample.

DNA sequencing of the VDR gene {#j_jomb-2018-0007_s_002_s_005}
------------------------------

The *VDR* gene was divided into the exons. Primers were designed for each fragment using PRIMER 3 program. Each exon and the UTR fragments were amplified by the Polymerase Chain Reaction (PCR) using the primers presented in *[Table I](#j_jomb-2018-0007_tab_001){ref-type="table"}* on the Applied Biosystems thermocycler. The PCR cycles consisted of three major steps of PCR, which were repeated for 35 cycles. Denaturation at 94 °C for 40 s; annealing at 54 °C 40s, and extension step at 72 °C for 40s. The PCR products were separated on 1.8% agarose gels to access the purity, and bands were visualized using ethidium bromide for imagining under ultraviolet light by gel documentation instrument. Each, clean PCR product obtained by amplification of the patients and control samples, was subjected to DNA sequencing. Sequencing of the *VDR* was carried out using Sanger Sequencing at the Core facility at King Faisal Specialist Hospital and Research Center using ABI PRISM 3730xi Genetic Analyzer (Cat\#3730S, Applied Biosystems, Foster city, CA 94404, USA). The resulting sequence was matched with the reference sequence, and genotypes were constructed for each patient and control.

###### 

Primers used for amplification of different fragments of the VDR Gene.

  Exone   Forward Primer (F) or Reverse Primer (R)   Sequence                 MT   Annealing Temp. (°C )
  ------- ------------------------------------------ ------------------------ ---- -----------------------
  1       F                                          GTGGCCTATAGGGTGGTTGA     79   
  R       CATACCTGGGCCCTGTAAGA                       79                       54   
  2       F                                          TGTGCTGATTGTCCCATTG      77   
  R       CAGTGGTTACAGGCTGACTCTG                     80                       60   
  3       F                                          CTTCCCACTGCTCCTGCTAC     80   
  R       ATCCTGGGTGGTATCCCTTC                       79                       60   
  4       F                                          CTGAGCTCCCTGGTGGTG       79   
  R       GGAGCTGAGAGGAGGGAAAA                       80                       60   
  5       F                                          GGCCTCATGTCTTCTGTTGG     79   
  R       GCTGGCAGCTACAGAGGAAG                       80                       60   
  6       F                                          CGAGTGTTAAAGCCCCTCCT     81   
  R       CTGCCCTCTGTCCCTACTCC                       79                       58   
  7       F                                          TGAACAGAACTGGGGTAGGG     79   
  R       TTGGGTAAGTCACCCCTTTC                       78                       54   
  8       F                                          GAAGGGTGACCTGTGGAGTC     79   
  R       AGGTTGCAGTGAGCCGAGAT                       78                       54   
  9       F                                          AGGAACACTCTTGTCCCTTCC    79   
  R       TCCCTGTTGGTGCCTAACTC                       79                       54   
  10      F                                          TCTTTTTCAGCTCCCAGATTC    77   
  R       GCTCTGCAAACCAGCAAAGT                       78                       60   
  11      F                                          TGGTATCACCGGTCAGCAGT     80   
  R       GTGAGGAGGGCTGCTGAGTA                       79                       58   
  UTR     F                                          CGAAGTGTTTGGCAATGAGA     77   
  R       GAGAGGGAGACCCCACTAGG                       81                       54   
  UTR     F                                          GGACAGAGACACCTGCACCT     80   
  R       AGGGCTTCCACCTCAACC                         79                       56   
  UTR     F                                          GTCCCTGTCACCAAGCTCAC     80   
  R       CTCTTAGCCCTGTGGGTGAA                       79                       56   
  UTR     F                                          GGGTCTGGAGAAGCAGTGAG     77   
  R       CATTCCCCAAACTCAAGCA                        80                       60   
  UTR     F                                          AGAAAGGCGTTCTTCGAGGT     78   
  R       TCAAACAAGGGTCTCTCCCTA                      78                       60   
  UTR     F                                          GGGGAGAACTTACATTGTGAAA   77   
  R       CGATCTCAGCTCACTGCAAC                       79                       60   
  UTR     F                                          AGGCTGAGGCAGAAGAATTG     78   
  R       TGAGGCAACAGCATTATCCA                       77                       60   
  UTR     F                                          CCAACCCATCAGAAGGAGAA     78   
  R       TTCCAGTTAGCCAGCCAGAG                       79                       60   
  UTR     F                                          GAGAAGGTGCCCCAAAATG      78   
  R       AATGATTCATCTCCCATAAGGTC                    77                       60   

MT = Melting Temperature

F= Forward Primer

R= Reverse Primer

Statistical analyses {#j_jomb-2018-0007_s_002_s_006}
--------------------

All data were analyzed using SAS (version 9.3). Data are presented as mean ± SD or as percentages. Correlation studies were conducted, and Pearson Correlation coefficient (r) and p values were obtained. The genotypes were obtained manually, by comparison, using DNAstar and the genotype and allele frequencies were calculated separately for the PCOS and control group. The patients and control data were compared, and odds ratio (OR), 2.5--95% confidence interval (CI), chi-square (χ^2^) and the p values were obtained. Allele frequencies were calculated and compared. Statistical significance was defined as p\< 0.05.

Results {#j_jomb-2018-0007_s_003}
=======

*[Table II](#j_jomb-2018-0007_tab_002){ref-type="table"}* presents the demographic data and hormone values obtained in the patients and control groups and the results of the Student's t test to show the significance of the difference between the two groups. Weight, Vit D and LH were higher in the PCOS patients, but age and BMI did not differ significantly. The Vit D level showed a positively skewed distribution in both groups. In the control group the minimum and maximum values ranged from 25.0--56.0 ng/mL (41.5 ± 7.5 ng/mL), while in the PCOS they were 30.0--60.0 ng/mL (47.2 ± 6.9 ng/mL) and the difference was statistically significant (p= 0.0324). The number of women with different levels of Vit D deficiency was calculated in the two groups, and the results are presented in *[Table III](#j_jomb-2018-0007_tab_003){ref-type="table"}*. None of the women had severe Vit D deficiency or highly elevated Vit D level. Majority had optimal Vit D level in both groups, but 25% of the PCOS had Vit D level in the upper normal range.

###### 

Levels of demographic variables and hormonal parameters in PCOS compared to the values in the normal healthy controls.

  Variable              Control (N = 17) Mean ± SD   PCOS (N = 16) Mean ± SD   P value
  --------------------- ---------------------------- ------------------------- ------------
  Weight (kg)           58.8 ± 12.1                  71.8 ± 11.4               0.0034 \*
  Height (cm)           162.2 ± 4.1                  155.2 ± 8.6               0.0078 \*
  BMI (kg/m^2^)         35.0 ± 9.1                   30.0 ± 5.7                0.0737
  Vit (ng/D mL) Level   41.5 ± 7.5                   47.2 ± 6.9                0.0324 \*
  LH (IU/L)             8.6 ± 1.3                    15.2 ± 2.3                \<.0001 \*
  FSH (IU/L)            5.8 ± 1.4                    6.2 ± 4.3                 0.7127

N = Total sample

SD = Standard deviation

(\*) = P --value less than 0.05

###### 

LVit D Level in PCOS and control.

  Vit D level                                 Control (N=17)   PCOS (N=16)
  ------------------------------------------- ---------------- -------------
  Suboptimal (20--30 ng/Vit mL) D provision   1(5.8)           -- (--)
  Optimal (30--50 Vit ng/D mL) level          14(82.3)         12(75)
  Upper (50--70 normal ng/mL)                 2(11.7)          4(25)
  Total                                       17(100)          16(100)

N= Total sample

n= Frequency

The level of Vit D was correlated with the demographic data and the hormones. The correlation coefficient (r), and the significance (p) are presented in *[Table IV](#j_jomb-2018-0007_tab_004){ref-type="table"}*. Both negative and positive correlations were observed but the only significant correlation was between Vit D and FSH.

###### 

The Correlation between Vit D Level and the studied variables.

  Correlation between Vit. D and:   Control (N = 17)   PCOS (N R = 16)            
  --------------------------------- ------------------ ----------------- -------- -------
  Age (year)                        -0.226             0.382             0.417    0.107
  Weight (kg)                       0.078              0.767             -0.351   0.182
  Height (cm)                       -0.258             0.318             -0.255   0.340
  BMI (kg/m^2^)                     0.161              0.536             -0.123   0.649
  LH (IU/L)                         0.090              0.731             0.023    0.934
  FSH (IU/L)                        0.665              0.004 \*          -0.328   0.214

N = Total Sample

(\*) = P -- value less than 0.05

A statistically significant positive correlation was seen between the level of Vit D and FSH in the control

group (p=0.004) (*[Figure 1](#j_jomb-2018-0007_fig_001){ref-type="fig"}*), but the correlation was negative and non-significant in the PCOS group. Also, there were no relationships between the level of Vit D and the other variables (age, weight, height, body mass index, LH) in both groups.

![Positive correlation between Vit D and FSH levels in the control group.](jomb-37-415-g001){#j_jomb-2018-0007_fig_001}

Sequencing of the *VDR* gene showed extensive polymorphisms in the PCOS patients and controls. *[Table V](#j_jomb-2018-0007_tab_005){ref-type="table"}* presents the SNPs in the *VDR* gene, identified in both the PCOS and control groups and the genotype and allele frequencies for each SNP. No significant differences were seen between the two groups.

###### 

SNPs identified, their location, genotype and allele frequencies in the PCOS and control group and the comparison between the two groups.

  SNP(location)                                Variation   Control               PCOS                   OR            Cl                            X^2^        P--value
  -------------------------------------------- ----------- --------------------- ---------------------- ------------- ----------------------------- ----------- -------------
  rs1381425375 (prime UTR variant A/C)         TT TG       16 (94.12) 1(5.88)    16(100) --             1.00 0.333    0.019--53.45 0.013--8.79      nan 0.97    1.000 0.324
                                               GG          --                    --                     1.000         0.19--53.457                  Nan         1.000
                                               T           33(97.0)              32(100)                2.91          0.114--74.076                 0.96        1.312
                                               G           1(2.9)                                       0.344         0.013--8.745                  0.96        1.359
  rs4307775 (Intron variant G/C)               CC CG       2 (11.76) 6 (35.29)   -- 6 (37.50)           0.181 5.000   0.008--4.268 0.199--125.785   2.01 1.75   0.156 0.185
                                               GG          9 (52.94)             10 (62.50)             5.526         0.234--130.343                2.01        0.156
                                               C           10(29.4)              6(18.75)               0.554         0.175--1.757                  1.02        0.312
                                               G           24(70.5)              26(81.25)              1.806         0.569--5726                   1.02        0.312
  rs4303288 (Intron variant A/C)               TT TG       3 (17.65) 9 (52.94)   3 (18.75) 3 (18.75)    0.500 0.333   0.073--3.435 0.042--2.631     0.50 1.12   0.477 0.288
                                               GG          5 (29.41)             10 (62.50)             2.000         0.291--13.738                 0.50        0.477
                                               T           15(44.1)              9(28.1)                0.496         0.178--1.382                  1.82        0.177
                                               G           19(55.8)              23(71.8)               2.018         0.723--5.627                  1.82        0.177
  rs111682935                                  CC          8 (47.06)             5 (31.25)              1.250         0.089--17.653                 0.03        0.868
  (prime UTR intron                            CA          7 (41.18)             10 (62.50)             2.286         0.522--10.011                 1.22        0.269
  variant G/A/T)                               AA          2 (11.76)             1 (6.25)               0.800         0.057--11.298                 0.03        0.868
                                               C           23(67.6)              20(62.5)               0.797         0.289--2.198                  0.19        0.660
                                               A           11(32.3)              12(37.5)               1.255         0.455--3.459                  0.19        0.660
  rs11168292 (intron variant C/A/G)            GG GC       8 (47.06) 7 (41.18)   5 (31.25) 10 (62.50)   1.250 2.286   0.089--17.653 0.522--10.011   0.03 1.22   0.868 0.269
                                               CC          2 (11.76)             1 (6.25)               0.800         0.057--11.298                 0.03        0.868
                                               G           23(67.6)              20(62.5)               0.797         0.289--2.198                  0.19        0.660
                                               C           11(32.3)              12(37.5)               1.255         0.455--3.459                  0.19        0.660
  rs1173979145                                 TT          16(94.12)             16(100)                1.000         0.019--53.457                 NAN         1.000
  (prime UTR A/G)                              TC          1(5.88)               --                     0.333         0.013--8.793                  0.97        0.324
                                               CC          --                    --                     1.000         0.019--53.457                 NAN         1.000
                                               T           33(97.0)              32(100)                2.910         0.114-- 74.079                0.96        1.359
                                               C           1(2.9)                                       0.344         0.013--8.745                  0.96        1.359
  rs11168276a                                  GG          16(94.12)             16(100)                3.000         0.114--79.135                 0.97        0.324
  (intron C/T)                                 GA          --                    --                     1.000         0.019--53.457                 NAN         1.000
                                               AA          1(5.88)               --                     0.333         0.013--8.793                  0.97        0.324
                                               G           32(94.1)              32(100)                5.00          0.231--108.254                1.94        0.600
                                               A           2(5.8)                                       0.200         0.009--4.330                  1.94        0.600
  rs2228570b                                   TT          1(5.88)               1 (6.25)               1.33          0.073--24.315                 0.04        0.845
  (start lostmissense variant A/C/G/T)         TC CC       4(23.53) 12(70.59)    6(37.50) 9(56.25)      1.500 0.750   0.071--31.575 0.41--13.677    0.07 0.04   0.793 0.845
                                               T           6                     8                      1.556         0.473--5.117                  0.53        0.465
                                               C           28                    24                     0.643         0.195--2.115                  0.53        0.465
  (rs121909790c missense variant C/G/T)        GG GA       17(100) --            15(93.75) 1 (6.25)     0.886 3.387   0.017--47.358 0.128--89.369   Nan 1.08    1.000 0.844
                                               AA          --                    --                     1.129         0.021--60.369                 1.10        0.295
                                               G           34(100)               31(96.8)               0.304         0.012--7.747                  1.08        0.844
                                               A                                 1(3.1)                 3.286         0.129--83.633                 1.08        0.844
  (rs10783218                                  CC          12(70.59)             15(93.75)              1.240         0.023--67.036                 Nan         1.000
  splice region variantintron                  CT          5(29.41)              1 (6.25)               0.160         0.016--1.560                  2.97        0.084
  variant3 prime UTR variant G/ A)             TT          --                    --                     0.806         0.015--43.598                 Nan         1.000
                                               C           29(85.2)              31(96.8)               5.345         0.589--48.524                 2.68        0.200
                                               T           5(14.7)               1(3.1)                 0.187         0.021--1.699                  2.68        0.200
  (rs11168267                                  CC          14(82.35)             11(68.75)              0.786         0.044--14.026                 0.03        0.869
  intron variant G/A/C)                        CT          2(11.76)              4(25)                  2.545         0.391--16.550                 1.00        0.318
                                               TT          1(5.88)               1 (6.25)               1.273         0.071--22.720                 0.03        0.869
                                               C           30                    26                     0.578         0.147--2.273                  0.63        0.505
                                               T           4                     6                      1.731         0.440--6.810                  0.63        0.505
  (rs11168266d                                 GG          --                    1 (6.25)               2.739         0.100--74.872                 0.87        0.350
  intron variant C/T)                          GA          7(41.18)              4(25)                  0.200         0.007--6.037                  1.53        0.216
                                               AA          10                    11(68.75)              0.365         0.013--9.979                  0.87        0.350
                                               G           7(2.05)               6(18.75)               0.890         0.264--3.003                  0.04        0.851
                                               A           27(79)                26(81.2)               1.123         0.333--3.791                  0.04        0.851
  (rs11168265e                                 GG          5(29.41)              5(31.25)               1.667         0.251--11.071                 0.28        0.595
  intron variantdownstream gene variant C/T)   GA AA       7(41.18) 5(29.41)     8(50) 3(18.75)         1.143 0.600   0.230--5.670 0.090--3.986     0.03 0.28   0.03 0.595
                                               G           17                    18                     1.286         0.488--3.390                  0.26        0.611
                                               A           17                    14                     0.778         0.295--2.051                  0.26        0.611
  (rs7975232 C/A)                              GG          2(11.76)              1(6.25)                0.438         0.032--5.926                  0.40        0.610
                                               GT          8(47.06)              7(43.75)               1.750         0.129--23.703                 0.18        0.671
                                               TT          7(41.18)              8(50)                  2.286         0.169--30.959                 0.40        0.527
                                               G           12                    9                      0.717         0.253--2.036                  0.39        0.532
                                               T           22                    23                     1.394         0.491--3.957                  0.39        0.532
  (rs731236f                                   TT          6(35.29)              4(25)                  0.667         0.102--4.354                  0.18        0.671
  synonymous variantA/G)                       TC          7(41.18)              8(50)                  1.714         0.339--8.676                  0.43        0.513
                                               CC          4(23.53)              4(25)                  1.500         0.230--9.796                  0.18        0.671
                                               T           19                    16                     0.789         0.300--2.080                  0.23        0.632
                                               C           15                    16                     1.267         0.481--3.337                  0.23        0.632
  (rs3858733g                                  AA          13 (76.47)            13 (81.25)             1.000         0.018--54.155                 Nan         1.000
  prime UTR variant T/G)                       CA          4 (23.53)             3 (18.75)              0.750         0.139--4.035                  0.11        0.737
                                               CC          --                    --                     1.000         0.018--54.100                 Nan         1.000
                                               A           30(88.2)              29(90.6)               1.289         0.265--6.267                  0.10        1.000
                                               C           4(11.7)               3(9.37)                0.776         0.160--3.773                  0.10        1.000
  (rs97293 prime                               AA          8 (47.06)             8 (50.00)              2.000         0.150--26.734                 0.28        0.595
  UTR variant G/C/T)                           CA          7 (41.18)             7 (43.75)              1.000         0.238--4.198                  0.00        1.000
                                               CC          2 (11.76)             1 (6.25)               0.0500        0.037--6.683                  0.287       0.595
                                               C           11                    9                      0.818         0.285--2.347                  0.14        0.708
                                               A           23                    23                     1.222         0.426--3.505                  0.14        0.708
  (rs28535633                                  GG          12 (70.59)            13 (81.25)             1.080         0.020--58.6555                Nan         1.000
  prime UTR variant C/T)                       GA          5(29.41)              3 (18.75)              0.554         0.108--2.833                  0.51        0.475
                                               AA          --                    --                     0.926         0.017--50.287                 Nan         1.000
                                               G           29(85.2)              29(90.6)               1.667         0.364--7.629                  0.44        0.709
                                               A           5(14.7)               3(9.37)                0.600         0.131--2.746                  0.44        0.709

Note: The superscripts (^a,b,c,d,e,f,g^) on the SNPs number, points to the SNPs that show significant differences in biochemical or hormonal parameters in different genotypes, as presented in [Table VI](#j_jomb-2018-0007_tab_006){ref-type="table"}

The study groups were assembled according to the genotypes of the different SNPs and the value of demographic and hormonal parameters, were obtained in each of the genotype. *[Table VI](#j_jomb-2018-0007_tab_006){ref-type="table"}* presents the value of only those parameters that showed significant difference in the different genotypes. As shown in *[Table VI](#j_jomb-2018-0007_tab_006){ref-type="table"}*, some of the variables were influenced by the genotype of a *VDR* SNP, while other showed no difference. Weight was significantly higher in females carrying GG genotype of rs2228570, AA genotype of rs11168266, AC genotype of rs3858733 and GG genotype of rs11168265, but BMI was higher only in the AC genotype of rs3858733. Among the hormonal parameters FSH was higher in the GG genotype of rs11168276 and LH in the GA genotype of rs121909790. Finally, Vit D levels were deficient in the GG genotype of rs11168276, CT genotype of rs731236 and GA genotype of rs11168265.

###### 

Effect of the SNP genotype in VDR on the studied variables in the study group.

  SNP            Variable                           Wild--type    Heterozygous   Vatiant        P--value
  -------------- ---------------------------------- ------------- -------------- -------------- ------------------
                 SNP genotyping                     GG            GA             AA             
  rs11168276a    Vitamin D (ng/mL)                  42.6±6.4      --             25.0±0.0       GG P=0.018 vs AA
                 FSH (IU/L)                         6.0±1.3       --             3.2 0.0        GG p=0.049 vs AA
                 SNP genotyping                     TT            TC             CC             
  rs2228570b     Weight (kg)                        85.0±0.0      61.5±12.8      55.7±9.6       TT P=vs 0.046 CC
  rs11168266d    SNP genotyping Weight (kg)         GG --         GA 51.7±7.3    AA 63.7±12.6   AA P=vs 0.039 AG
                 SNP genotyping                     AA            AC             CC             
  rs3858733g     Weight (kg)                        55.6±9.2      69.0±16.1      --             AC p=vs 0.049 AA
                 BMI (kg/m^2^)                      32.5±7.7      42.9±9.9       --             AC p=vs 0.042 AA
                 SNP genotyping                     GG            GA             AA             
  rs121909790c   LH (IU/L)                          15.6±1.9      47.0±0.0       --             GG P=0.012 vs GA
                 SNP genotyping                     GG            GA             AA             
  rs11168265e    Weight (kg)                        77.7±10.3     73.2±10.3      58.2±3.7       GG p=0.043 vs AA
                 Vitamin D (ng/mL) SNP genotyping   45.0±2.4 TT   44.8±6.6 CT    57.3±2.3 CC    AA P=vs 0.008 AG
  rs731236f      VitaminD (ng/mL)                   46.0±1.2      44.0±6.7       54.8±5.5       CC P=vs 0.024 CT

Note: The superscripts (^a,b,c,d,e,f,g,h^) on the SNPs link these SNPs to the SNPs in the *[Table V](#j_jomb-2018-0007_tab_005){ref-type="table"}*

Discussion {#j_jomb-2018-0007_s_004}
==========

Our interest developed in this study on patients with PCOS, since it is shown in many investigations that Vit D and VDR play several essential roles in the female reproductive organs. The VDR spreads over most of the female reproductive tissues and are involved in uterus development during preparation for the process of embryo implantation ([@j_jomb-2018-0007_ref_028], [@j_jomb-2018-0007_ref_029]). In addition, the VDR are also present on the ovaries and are involved in the formation of vesicles process (folliculogenesis) and the synthesis of sex hormones (steroidogenesis of sex hormones) ([@j_jomb-2018-0007_ref_006]). However, our results in Saudis compared with or contrasted several of the findings reporting Vit D deficiency in PCOS.

In our study, the females suffering from PCOS were 16 in number and matched in age and BMI with the control group (17 in number). Vit D levels were higher in the PCOS, compared to the control group and the difference was significant statistically. The optimal level according to the »Reference Ranges« as set by the Mayo Medical Laboratories ([@j_jomb-2018-0007_ref_030]) is 25--80 ng/mL In our study all the females suffering from PCOS had optimal Vit D levels and amongst the normal controls only 1/17 (5.8%) had sub--optimal Vit D levels, indicating that in Saudis Vit D deficiency is not involved in the pathogenesis of PCOS. These results are in line with those reported by Wehr and colleagues on Austrian population ([@j_jomb-2018-0007_ref_010]).

When the hormone levels were compared, the level of LH was significantly higher in the PCOS compared to the controls, while the FSH levels did not differ significantly. However the LH/FSH ratio was significantly higher in the PCOS compared to the controls. These results are in agreement with the results of Polson et al. ([@j_jomb-2018-0007_ref_031]), Taylor et al. ([@j_jomb-2018-0007_ref_032]) and Daghestani et al. ([@j_jomb-2018-0007_ref_033]), but disagree with the results of Norman et al. ([@j_jomb-2018-0007_ref_034]) and Adams et al. ([@j_jomb-2018-0007_ref_035]). Other studies have also reported that PCOS is characterized by high levels of LH due to low levels of estrogen and progesterone resulting from lack of ovulation process ([@j_jomb-2018-0007_ref_036]). In addition, this may be due to the high sensitivity of the pituitary gland to gonadotropin-releasing hormone (GnRH), as pointed out by Hayes et al. ([@j_jomb-2018-0007_ref_037]).

Interestingly, when Vit D level was correlated with all the studied parameters, a positive correlation was identified between the level of Vit D and FSH in the control group only. In the PCOS patients Vit D correlated negatively with FSH, but the correlation was not statistically significant ([@j_jomb-2018-0007_ref_038]). In an earlier study Zolkova et al. ([@j_jomb-2018-0007_ref_039]) had shown that there was an improvement in FSH level with specific doses of Vit D. However, a recent report failed to show any correlation between Vit D and FSH and LH in young females ([@j_jomb-2018-0007_ref_040]).

The present study also failed to show any association between Vit. D and BMI, though earlier investigations showed that Vit D associates with BMI ([@j_jomb-2018-0007_ref_010], [@j_jomb-2018-0007_ref_011], [@j_jomb-2018-0007_ref_013]). Recently, Duhil de Benaze ([@j_jomb-2018-0007_ref_040]) also failed to show any association between Vit D and BMI.

In the present study, the unique feature was that we conducted a comprehensive survey of the *VDR* gene by sequencing all exons and part of the introns on both sides of the exon. Our genotyping results showed that there were no significant associations of any of SNPs in *VDR* gene with PCOs in Saudi women. These results are in line with the results reported by Wehr et al. ([@j_jomb-2018-0007_ref_021]) who did not find any association between 8 polymorphisms in *VDR* gene and PCOS. In our study the frequency of genotypes and alleles of several of the SNPs were very different when the PCOS patients were compared with the controls, but the statistical significance was not achieved. This is probably due to the smaller number of sample size used in this study.

Interestingly, literature review revealed that there are remarkable population variations in the association between Vit D deficiency and genetic variants of *VDR*. Mahmoudi et al. ([@j_jomb-2018-0007_ref_012]) showed significant association of rs7975232 (GT) in *VDR* with severity of the disease in Iranian population, while no such association was found in Egyptians, despite significantly lower Vit D levels in PCOS ([@j_jomb-2018-0007_ref_041]). In Silesian women endogenous Vit D deficiency and *VDR* polymorphisms were not associated with »classic« PCOS phenotype ([@j_jomb-2018-0007_ref_042]), though, in the South Indian females the *VDR* gene polymorphism was shown as a remarkable inheritable risk factor for PCOS ([@j_jomb-2018-0007_ref_043]).

Many of the SNPs identified in our study have not been reported in any of the previous studies. Hence, studies on larger study groups are required to confirm association if any between the SNP and PCOS development.

Furthermore, in our study we also found that some of the genotypes affected the levels of the anthropometric and hormonal parameters. The variant rs731236 (CC) associated with the level of Vit D in the PCOs group, but not with LH level. This result is contrary to studies conducted by Ranjzad et al. ([@j_jomb-2018-0007_ref_025]) and Bagheri et al. ([@j_jomb-2018-0007_ref_023]) who showed association between Vit D and the level of LH. We also identified several relationships between variables of the study and SNP genotypes which were not mentioned in previous studies on *VDR* and PCOS. These results show that the inter-individual variations may be a result of variations in the genotype of *VDR*. Further detailed studies are warranted to provide a clearer picture of the associations.

The major limitation of this study was the small sample size. However, as a pilot study it provided several interesting facts, which need confirmation by further more detailed studies. Secondly, during this study, the level of insulin was not measured. So we could not provide evidence to validate a number of studies that associate Vit D with insulin resistance. Also, the level of Vit D and its association with insulin resistance in type II diabetes could not be confirmed ([@j_jomb-2018-0007_ref_013], [@j_jomb-2018-0007_ref_021]). Further studies on a larger sample size are required to confirm these results.

Conclusion {#j_jomb-2018-0007_s_005}
==========

This study shows that in Saudis Vit D deficiency does not contribute to PCOS development and comparing the results with those in the literature highlight the wide variations that exist in the prevalence of Vit D deficiency in PCOS in different populations. During this study, extensive polymorphisms are revealed in the *VDR* gene on sequencing. Though no significant differences are observed in the frequency of these variants in the Saudi PCOS and normal population, but several variants influence the demographic and hormonal parameter levels in the studied population. Since extensive population differences exist and studies on *VDR* variants are few, it is suggested that further detailed studies are conducted to obtain a clearer picture of the association between *VDR* gene polymorphisms and PCOS etiology.
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